Becton looks to separate biosciences and diagnostic solutions after upbeat quarterly results
Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device maker aims to focus on its core business.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of ...
BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.
Becton Dickinson (NYSE:BDX) stock was down 3% in morning trading Thursday, the day after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate ...
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
The Financial Times reports today that an activist investor wants BD (NYSE:BDX) to sell off its Life Sciences business unit.
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
Consensus is $14.35. Sees FY25 revenue $21.7B-$21.9B vs. previous view $21.9B-$22.1B, consensus $21.93B.Maximize Your Portfolio with Data ...
Whiting-Turner Contracting, Suffolk Construction, Skanska USA, STO Building Group, Truebeck Construction, and Hensel Phelps ...
BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback